SEC Filing Summary: Klotho Neurosciences, Inc. (KLTO)
Business Context and Reporting Period
This Form 8-K was filed by Klotho Neurosciences, Inc. (formerly ANEW Medical, Inc.) on October 21, 2024, reporting an event that occurred on October 14, 2024. The Company is a Delaware corporation with its principal executive offices in Omaha, NE. It is designated as an emerging growth company. The filing addresses a regulatory compliance issue regarding its listing on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing status notification and does not contain financial performance data.
Material Changes
The material change reported is the receipt of a delinquency notification letter from Nasdaq on October 15, 2024. The Company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted 180 calendar days, until April 14, 2025, to regain compliance.
- Compliance Requirement: To avoid delisting, the closing bid price of the common stock must be at least $1.00 for a minimum of ten consecutive business days prior to April 14, 2025.
- Risk of Delisting: If the Company fails to meet the compliance requirement within the specified timeframe, its common stock will be subject to delisting from Nasdaq.
Investor Verification Checklist
- Verify the current trading price of KLTO common stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if the compliance window is met.
- Review subsequent filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Confirm the exact expiration date of the compliance period (April 14, 2025) for timeline planning.